Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
India business contributes to a stellar performance
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Adjusted PAT declined 18.8% YoY
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
